Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia, Clinical Trials and Observations Letter to Blood Source Type: research